Stock A244460 OLIPASS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials OLIPASS Corporation

Equities

A244460

KR7244460002

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
519 KRW -2.81% Intraday chart for OLIPASS Corporation 0.00% -32.95%
03-18 OLIPASS Corporation announced that it has received KRW 3.5 billion in funding CI
03-06 OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding CI

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 373,324 448,866 269,557 187,565
Enterprise Value (EV) 1 362,576 419,679 251,266 181,370
P/E ratio -7.92 x -18.8 x -10.8 x -7.66 x
Yield - - - -
Capitalization / Revenue 219 x 157 x 316 x 81.7 x
EV / Revenue 213 x 147 x 295 x 79 x
EV / EBITDA -19.4 x -20.5 x -11.4 x -8.5 x
EV / FCF -9.84 x -24 x -18.9 x -24.8 x
FCF Yield -10.2% -4.18% -5.28% -4.03%
Price to Book 19.4 x 10.8 x 9.33 x 19.6 x
Nbr of stocks (in thousands) 23,829 24,351 29,332 30,799
Reference price 2 15,667 18,433 9,190 6,090
Announcement Date 17/03/20 10/03/21 14/03/22 20/03/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022
Net sales 1 1,705 2,861 851.8 2,296
EBITDA 1 -18,703 -20,482 -22,116 -21,343
EBIT 1 -21,666 -23,698 -25,133 -24,130
Operating Margin -1,270.51% -828.4% -2,950.71% -1,050.94%
Earnings before Tax (EBT) 1 -46,427 -24,579 -25,724 -24,752
Net income 1 -45,640 -24,183 -25,135 -24,168
Net margin -2,676.37% -845.35% -2,950.84% -1,052.59%
EPS 2 -1,978 -980.0 -851.0 -795.0
Free Cash Flow 1 -36,863 -17,522 -13,264 -7,302
FCF margin -2,161.67% -612.5% -1,557.19% -318.05%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 17/03/20 10/03/21 14/03/22 20/03/23
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022
Net Debt 1 - - - -
Net Cash position 1 10,748 29,187 18,291 6,195
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 -36,863 -17,522 -13,264 -7,302
ROE (net income / shareholders' equity) 585% -79.3% -70.1% -126%
ROA (Net income/ Total Assets) -30.4% -24.1% -27.5% -42.5%
Assets 1 150,315 100,379 91,480 56,894
Book Value Per Share 2 809.0 1,710 985.0 310.0
Cash Flow per Share 2 1,258 1,997 293.0 425.0
Capex 1 784 2,156 1,124 157
Capex / Sales 45.98% 75.38% 132.01% 6.82%
Announcement Date 17/03/20 10/03/21 14/03/22 20/03/23
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
OLIPASS CORPORATION Stock OLIPASS Corporation
-32.95% 13.24M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.33% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.11% 106B
BIONTECH SE Stock BioNTech SE
-12.56% 22.24B
ARGENX SE Stock argenx SE
-3.70% 21.25B
GENMAB A/S Stock Genmab A/S
-6.03% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.86% 16.81B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.10% 13.94B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.57% 12.54B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A244460 Stock
  4. Financials OLIPASS Corporation